128 related articles for article (PubMed ID: 15569200)
1. Surgical treatment planning in newly diagnosed breast cancer patients at high risk for BRCA-1 or BRCA-2 mutation.
Chung MA; Cady B
Breast J; 2004; 10(6):473-4. PubMed ID: 15569200
[No Abstract] [Full Text] [Related]
2. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
[TBL] [Abstract][Full Text] [Related]
3. Numerous high-risk epithelial lesions in familial breast cancer.
Hoogerbrugge N; Bult P; Bonenkamp JJ; Ligtenberg MJ; Kiemeney LA; de Hullu JA; Boetes C; Niermeijer MF; Brunner HG
Eur J Cancer; 2006 Oct; 42(15):2492-8. PubMed ID: 16908132
[TBL] [Abstract][Full Text] [Related]
4. Management of the BRCA mutation carrier or high-risk patient.
Bordeleau LJ; Lipa JE; Neligan PC
Clin Plast Surg; 2007 Jan; 34(1):15-27; abstract v. PubMed ID: 17307068
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?
Leunen K; Drijkoningen M; Neven P; Christiaens MR; Van Ongeval C; Legius E; Amant F; Berteloot P; Vergote I
Breast Cancer Res Treat; 2008 Jan; 107(1):79-86. PubMed ID: 17431765
[TBL] [Abstract][Full Text] [Related]
6. Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations.
Silva E; Lynch H
Breast J; 2006; 12(3):280-1; author reply 282-4. PubMed ID: 16684334
[No Abstract] [Full Text] [Related]
7. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
8. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.
Evans DG; Lalloo F; Hopwood P; Maurice A; Baildam A; Brain A; Barr L; Howell A
Eur J Surg Oncol; 2005 Dec; 31(10):1112-8. PubMed ID: 16005602
[TBL] [Abstract][Full Text] [Related]
9. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret.
van Dijk S; van Roosmalen MS; Otten W; Stalmeier PF
J Clin Oncol; 2008 May; 26(14):2358-63. PubMed ID: 18467728
[TBL] [Abstract][Full Text] [Related]
10. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Fatouros M; Baltoyiannis G; Roukos DH
Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
[TBL] [Abstract][Full Text] [Related]
11. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
[TBL] [Abstract][Full Text] [Related]
12. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer after bilateral risk-reducing mastectomy.
Skytte AB; Crüger D; Gerster M; Laenkholm AV; Lang C; Brøndum-Nielsen K; Andersen MK; Sunde L; Kølvraa S; Gerdes AM
Clin Genet; 2011 May; 79(5):431-7. PubMed ID: 21199491
[TBL] [Abstract][Full Text] [Related]
14. Can genetic testing guide treatment in breast cancer?
Tutt A; Ashworth A
Eur J Cancer; 2008 Dec; 44(18):2774-80. PubMed ID: 19027287
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic surgery in the complex decision-making management of BRCA mutation carriers.
Briasoulis E; Ziogas D; Fatouros M
Ann Surg Oncol; 2008 Jun; 15(6):1788-90; author reply 1791-2. PubMed ID: 18197455
[No Abstract] [Full Text] [Related]
16. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers.
Matloff ET; Barnett RE; Bober SL
Cancer J; 2009; 15(1):15-8. PubMed ID: 19197168
[TBL] [Abstract][Full Text] [Related]
18. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
19. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
[TBL] [Abstract][Full Text] [Related]
20. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]